Myasthenia Gravis
From the Journals
Autoimmune Disease Risk May Rise Following Cushing Disease Remission After Surgery
The findings suggested the need for closer postsurgical monitoring of patients with a family history of autoimmune disease.
Conference Coverage
Novel myasthenia gravis therapies bring opportunities, challenges
Minimal disease manifestation is meaningful for patients, but should be weighed against potential side effects.
Conference Coverage
Newly approved myasthenia gravis drug shows sustained benefits in early responders
“This self-administered medication allows patients to be more independent and can even travel since it is not dependent on an infusion center.”
Conference Coverage
U.S. study finds unexpectedly high prevalence of myasthenia gravis
A study of the NIH All of Us database shows a higher prevalence of myasthenia gravis than what has been reported in previous studies.
Conference Coverage
In myasthenia gravis, antibodies pass open-label tests
New class of therapies interfere with IgG recycling and have similar efficacy across multiple cycles of treatment.
FDA/CDC
Myasthenia gravis drug gets FDA nod
Rozanolixizumab is the first FDA-approved treatment for adults with both subtypes.
Conference Recap
Clinical Advances in Myasthenia Gravis From AAN 2023
Encouraging data for three novel therapies and the association between fatigue and disease severity are among the clinical advances from AAN 2023...
Conference Coverage
U.S. incidence, prevalence of myasthenia gravis is rising
These new estimates are “significantly higher” than those from a prior U.S. analysis from 2003.
Rare Diseases Report 2022
Myasthenia gravis: Finding strength in treatment options
Although treatment might have once been considered stagnant, newer expert consensus and novel research are generating optimism for innovative...
Recap
Evolving Treatment Options for Generalized Myasthenia Gravis
Dr Raghav Govindarajan discusses evolving treatment options for patients with myasthenia gravis, focusing on data presented at AAN 2022, including...